Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
NCT ID: NCT06772584
Last Updated: 2025-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2024-01-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin . For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%.8 However, numerous reports of side effects, some lethal, have led to a decline in its use.
Since Dimson in 1977 reported on the effects of desmopressinl" several double blind, placebo controlled studies have shown the efficacy of the drug often with rapid effect but also often with immediate relapse after ending treatment.
While one of theory of nocturnal enuresis is deep sleep in children , this the main cornerstone in using Alarm as line of management .
On the other hand drugs used in rehabitation of sleep rhythm seems to be with great benefits in management as GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; antiinflammation; anti-tumor activities; anti-aging , and improve night sleep rhythm
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
NCT06771128
Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
NCT06285006
Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population
NCT02584231
Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
NCT05617664
Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
NCT01078753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin . For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%.8 However, numerous reports of side effects, some lethal, have led to a decline in its use.
Since Dimson in 1977 reported on the effects of desmopressinl" several double blind, placebo controlled studies have shown the efficacy of the drug often with rapid effect but also often with immediate relapse after ending treatment.
While one of theory of nocturnal enuresis is deep sleep in children , this the main cornerstone in using Alarm as line of management .
On the other hand drugs used in rehabitation of sleep rhythm seems to be with great benefits in management as GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; antiinflammation; anti-tumor activities; anti-aging , and improve night sleep rhythm
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omegapress 0.2
Omegapress 0.2 was been taken by the pt
Desmopressin Acetate 0.2 mg Tablets
3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
Ginkobiloba
Drug was taken by the pt
Ginkgobiloba
Group s take it as treatment of deep sleep in nectornal enuresis
Omegapress+ ginkgobiloba
Both drugs were taken
Desmopressin Acetate 0.2 mg Tablets
3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
Ginkgobiloba
Group s take it as treatment of deep sleep in nectornal enuresis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desmopressin Acetate 0.2 mg Tablets
3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
Ginkgobiloba
Group s take it as treatment of deep sleep in nectornal enuresis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menoufia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hossam Kandeel
Assistant lecturer of urology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Menofia university
Cairo, State Or Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5/2024UROL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.